{"title":"血管紧张素转换酶抑制剂使用者的高发咳嗽","authors":"J. Nasser, Khadija Al Aradi, K. S. Ebrahim","doi":"10.12816/0047558","DOIUrl":null,"url":null,"abstract":"Pharmacologic management of hypertension includes many major classes of drugs. Angiotensin-Converting Enzyme Inhibitors (ACEI) is one of them. In fact, ACEI is considered the first choice in many recent guidelines3,4. ACEI have many indications in addition to blood pressure lowering. For example, many studies had found consistent beneficial effects in postmyocardial infarction, heart failure, and chronic kidney disease patients5. This led to the widespread use of these agents.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"High Incidence of Cough among Users of Angiotensin-Converting Enzyme Inhibitors\",\"authors\":\"J. Nasser, Khadija Al Aradi, K. S. Ebrahim\",\"doi\":\"10.12816/0047558\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pharmacologic management of hypertension includes many major classes of drugs. Angiotensin-Converting Enzyme Inhibitors (ACEI) is one of them. In fact, ACEI is considered the first choice in many recent guidelines3,4. ACEI have many indications in addition to blood pressure lowering. For example, many studies had found consistent beneficial effects in postmyocardial infarction, heart failure, and chronic kidney disease patients5. This led to the widespread use of these agents.\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2018-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12816/0047558\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12816/0047558","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
High Incidence of Cough among Users of Angiotensin-Converting Enzyme Inhibitors
Pharmacologic management of hypertension includes many major classes of drugs. Angiotensin-Converting Enzyme Inhibitors (ACEI) is one of them. In fact, ACEI is considered the first choice in many recent guidelines3,4. ACEI have many indications in addition to blood pressure lowering. For example, many studies had found consistent beneficial effects in postmyocardial infarction, heart failure, and chronic kidney disease patients5. This led to the widespread use of these agents.